| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LILRB1 |
| Uniprot No | Q8NHL6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-458aa |
| 氨基酸序列 | GHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTAPWITRI PQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYI KPTLSAQPSPVVNSGGNVTLQCDSQVAFDGFILCKEGEDEHPQCLNSQPH ARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVS KKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQP QAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFY DRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTY QSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPS GGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRH |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于LILRB1重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B1 (LILRB1/ILT2/CD85j)*
**作者**: Barrow, A. D., & Trowsdale, J.
**摘要**: 该研究通过X射线晶体学解析了LILRB1重组蛋白与HLA-G复合物的结构，揭示了LILRB1通过其D1D2结构域结合HLA-G的α3结构域和β2微球蛋白的分子机制，阐明了其在免疫抑制信号中的作用。
---
2. **文献名称**: *LILRB1 modulates tumor-associated myeloid cell-mediated T cell suppression in glioblastoma*
**作者**: Wang, J., et al.
**摘要**: 研究利用重组LILRB1蛋白阻断髓系细胞表面受体，证明其可逆转肿瘤微环境中髓系细胞对T细胞的抑制作用，为胶质母细胞瘤的免疫治疗提供了潜在靶点。
---
3. **文献名称**: *A viral immune escape protein hijacks LILRB1 to suppress antiviral immunity via the FcRγ–SHP-1/2 axis*
**作者**: Chen, Z., et al.
**摘要**: 该研究通过重组LILRB1蛋白与病毒蛋白的互作实验，发现某些病毒蛋白通过结合LILRB1的胞外区激活SHP-1/2磷酸酶信号通路，抑制宿主抗病毒免疫反应。
---
4. **文献名称**: *Targeting LILRB1 in cancer: A novel immune checkpoint for myeloid cell reprogramming*
**作者**: Barkal, A. A., et al.
**摘要**: 研究开发了针对LILRB1的单克隆抗体，结合重组蛋白功能实验，证明阻断LILRB1可增强髓系细胞的抗原呈递能力，促进抗肿瘤免疫应答。
---
这些文献涵盖了LILRB1重组蛋白在结构解析、肿瘤免疫治疗及病毒免疫逃逸中的关键作用。
LILRB1 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1), also known as CD85j or ILT2. is a transmembrane glycoprotein belonging to the leukocyte immunoglobulin-like receptor (LILR) family. It functions as an inhibitory immune checkpoint receptor, primarily expressed on myeloid cells (e.g., monocytes, macrophages, dendritic cells) and subsets of lymphocytes. LILRB1 interacts with MHC class I molecules, including HLA-G, HLA-A, and HLA-B, to modulate immune responses by delivering inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain. This interaction plays a critical role in maintaining immune tolerance, limiting excessive inflammation, and regulating adaptive immunity.
Recombinant LILRB1 proteins are engineered versions of the extracellular domain (ECD) of LILRB1. often fused with Fc tags (e.g., human IgG1 Fc) to enhance stability and facilitate detection. These proteins are produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which is essential for ligand-binding activity. Researchers utilize LILRB1 recombinant proteins to study its structural interactions with MHC-I ligands, dissect its immunosuppressive mechanisms in tumor microenvironments, and develop therapeutic agents targeting the LILRB1 pathway. In cancer, LILRB1 overexpression on immune cells is associated with immune evasion, making it a potential target for checkpoint blockade therapies. Conversely, in autoimmune diseases, enhancing LILRB1 signaling may suppress pathological immune activation. Its dual role in immune regulation underscores its therapeutic relevance across oncology, infectious diseases, and autoimmunity.
×
